Summary

• The Board of Directors of the Company today announces its intention to resolve on the Rights Issue, provided that the shareholders at the Extraordinary General Meeting on March 13, 2026, authorize the Board of Directors to decide on a new share issue, etc. Notice of the Extraordinary General Meeting will be announced in a separate press release.
• Upon full subscription, the Rights Issue will provide the Company with approximately SEK 60 million before transaction costs. The net proceeds from the rights issue are primarily intended to be used to accelerate the U.S. and European commercial rollout, strengthen distributor support, and fully fund the next major product expansion, EndoDrill^® EBUS for lung cancer, through FDA 510(k) clearance, pilot clinical trials, and introductory launch.
• The subscription price in the Rights Issue will correspond to a TERP discount of at least 35 percent on the volume-weighted average price of the Company's share on Spotlight Stock Market during the period from and including March 5, 2026, up to and including March 18, 2026, however not lower than the quota value of Company's share. The Board of Directors' resolution and the final terms of the Rights Issue, including the subscription price, are expected to be announced on March 18, 2026.
• The subscription period for the Rights Issue is expected to run from and including March 30, 2026, up to and including April 13, 2026. The last day of trading in the Company's shares with the right to receive subscription rights is expected to be March 24, 2026.
• In total, the Rights Issue is covered by subscription commitments, subscription intentions, and guarantee commitments of up to approximately SEK 42 million, corresponding to approximately 70 percent of the Rights Issue.
• No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish an information document (the "Information Document") in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the "Prospectus Regulation").

"BiBBInstruments is now entering an exciting phase, marked by the formal U.S. launch of EndoDrill^® GI, strong interest from leading American clinics, and several important clinical and strategic advancements. We now want to carry out a public offering that will broaden the ownership base and finance BiBB during 2026-2027, as well as enable a number of value-creating activities, such as broader commercialization in the US, launch in Europe, development of a new product variant for lung cancer, and continued evidence building through clinical studies.", comments Fredrik Lindblad, CEO.

Jan Poulsen, CEO at Life Science Invest Fund ("LSIF"), comments: "We invested in BiBBInstruments in the financing round a year ago, and BiBBInstruments has over the past year delivered good progress on its commercialization plans, so it is only natural that we at LSIF, as long term owners, now take the lead in this new financing by committing to subscribe to our full pro rata share in the Rights Issue and on top of this act as the main guarantor with a guarantee commitment of SEK 11.5 million."

Background and rationale

BiBBInstruments is a cancer diagnostics company that develops and manufactures EndoDrill^®, the world's first series of powered endoscopic biopsy instruments. EndoDrill^® aims to enable the sampling of high-quality core biopsies that provide complete diagnostics, thereby creating the conditions for optimal and rapid cancer treatment. In 2023, BiBBInstruments received 510(k) clearance from the US Food and Drug Administration (FDA) for its first product variant, EndoDrill^® GI. In 2024, CE marking was granted in accordance with the EU Medical Device Regulation (MDR) for all three product variants - EndoDrill^® GI, EndoDrill^® EBUS, and EndoDrill^® URO - making EndoDrill^® the first powered biopsy system approved in both the US and Europe. The EndoDrill^® system consists of sterile single-use instruments and a proprietary motor unit.

In recent years, BiBB has conducted preclinical comparisons, a Swedish pilot study, two US case series, an initial US clinical project, and a retrospective multicenter study with EndoDrill® GI. The results from these studies in Europe and the US show a very high diagnostic accuracy, often after only a single needle puncture in the studies conducted. These clinical results form the basis for the Company's ongoing commercialization of EndoDrill^® GI.

BiBBInstruments has initiated commercialization in the US with EndoDrill^® GI. In June 2025, the Company entered into a distribution agreement with TaeWoong Medical USA, which was followed by a targeted launch to a selection of TaeWoong's reference customers in the fall of 2025. A broad launch in TaeWoong's national network is planned for 2026. In September 2025, the Company received its first commercial order for products worth approximately SEK 110,000, followed by new orders from TaeWoong totaling approximately SEK 300,000 in the fourth quarter of 2025. TaeWoong has thus established several paying reference hospitals in the US, which constitutes an important platform for the planned broader national launch in 2026.

The net proceeds from the Rights Issue are primarily intended to be used to accelerate the commercial launch in the US and initiate the launch in Europe, strengthen distributor support, and finance the next major product expansion, EndoDrill® EBUS for lung cancer, including FDA 510(k) approval, clinical pilot studies, and launch start.

The net proceeds from the Rights Offering will also support key clinical programs, including the planned multicenter study for EndoDrill^® GI, and drive cost optimization initiatives, such as improved purchasing, volume-based reductions in material costs, and implementation of internal systems necessary to streamline administrative processes and enable scalable and efficient commercial expansion.

Rights issue
Provided that the shareholders at the Extraordinary General Meeting on March 13, 2026, authorize the Board of Directors of the Company to resolve on a new share issue and resolve on amendments to the Articles of Association, the Board of Directors of the Company is expected to resolve on the Rights Issue no later than March 18, 2026. The subscription period in the Rights Issue is expected to run from and including March 30, 2026, up to and including April 13, 2026, and, if fully subscribed, will raise approximately SEK 60 million for the Company before transaction costs. The subscription price in the Rights Issue will correspond to a TERP discount of at least 35 percent on the volume-weighted average price on Spotlight Stock Market during the period from and including March 5, 2026, up to and including March 18, 2026, however not lower than the quota value of Company's share.

The Board's decision and the final terms of the Rights Issue, including the subscription price, are expected to be announced on March 18, 2026. For further information on the timetable, please refer to the section "Preliminary timetable" below.

Subscription commitments, subscription intentions, and guarantee commitments
The Company has received subscription commitments from a number of existing major shareholders, including Life Science Invest Fund, totaling approximately SEK 10 million, corresponding to approximately 17 percent of the Rights Issue. In addition, all members of the Company's Board of Directors and management, including CEO Fredrik Lindblad, have expressed their intention to subscribe for shares in the Rights Issue, amounting to a total of approximately SEK 1 million, corresponding to approximately 1 percent of the Rights Issue. Members of the Company's Board of Directors and management are prevented, under applicable rules on market abuse, from entering into undertakings to subscribe for shares in the Rights Issue, as a result of the Company being in a so-called closed period until the publication of the year-end report for 2025, and are expected to enter into binding subscription undertakings after the closed period has ended. No compensation will be paid for entered subscription commitments or subscription intentions.

The Company has also entered into agreements with certain existing shareholders and a number of external investors regarding guarantee commitments totaling approximately SEK 31 million, corresponding to approximately 52 percent of the Rights Issue. According to the guarantee agreements, cash compensation of 12 percent of the guaranteed amount will be paid, corresponding to a total of approximately SEK 4 MSEK, or 14 percent of the guaranteed amount in the form of newly issued shares in the Company, with the same terms and conditions as shares in the Rights Issue, including the subscription price in the Rights Issue.

In total, the Rights Issue is covered by subscription commitments, subscription intentions, and guarantee commitments of up to approximately SEK 42 million, corresponding to approximately 70 percent of the Rights Issue. For the avoidance of doubt, the guarantee commitments are so-called bottom guarantee commitments, covering subscription up to the level of approximately 70 percent of the Rights Issue. Neither the subscription commitments, subscription intentions nor guarantee commitments are secured by bank guarantees, blocked funds, pledges or similar arrangements.

In order to enable the issue of shares as guarantee compensation to the guarantors who choose to receive guarantee compensation in the form of newly issued shares, the Board of Directors has proposed that the Extraordinary General Meeting on March 13, 2026, also resolve to authorize the Board of Directors to resolve on the issue of such shares to the guarantors.

Preliminary timetable for the Rights Issue

Lock-up undertakings

Shareholding members of the Company's Board of Directors and the CEO have, subject to certain exceptions, undertaken not to sell shares or other financial instruments in the Company for a period of 180 calendar days after the announcement of the Rights Issue (this press release), provided that the Rights Issue is carried out.

Extraordinary general meeting

The Board of Directors' intention to resolve on the Rights Issue is conditional upon the shareholders at the Extraordinary General Meeting on March 13, 2026, authorizing the Board of Directors to resolve on a new issue and resolving to amend the Articles of Association in accordance with the Board of Directors' proposal to the Extraordinary General Meeting. Notice of the Extraordinary General Meeting will be announced in a separate press release.

Information document
No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish the Information Document in the form prescribed by Annex IX of the Prospectus Regulation. The Information Document will be held available on the Company's website on or around March 24, 2026.

Advisors

Vator Securities is acting as financial advisor to the Company and Foyen Advokatfirma is acting as legal advisor to the Company in connection with the Rights Issue.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO

Email: fredrik.lindblad@bibbinstruments.com

Phone: +46 70 899 94 86

www.bibbinstruments.com 

This information is information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at the time specified by the Company's news distributor at the time of publication of this press release.

About BiBBInstruments AB

BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. EndoDrill® enables tissue sampling with high precision and quality, with the aim of improving the diagnosis of several serious cancers, including those of the stomach, pancreas, liver, lungs, and bladder. BiBB's product portfolio targets the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments - the most advanced and fastest-growing segment of endoscopy. In 2023, BiBB's lead product EndoDrill® GI received 510(k) clearance from the U.S. FDA. In early 2024, CE marking was obtained under the new MDR regulatory framework for all three product variants: EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO. As a result, EndoDrill® became the first market-cleared electric-driven endoscopic biopsy system in both the U.S. and Europe. EndoDrill® consists of sterile, single-use instruments paired with a dedicated drive system. BiBB was founded in 2013 by Dr. Charles Walther - cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital - and is headquartered at Medicon Village in Lund, Sweden. BiBB's share (ticker: BIBB) is listed on the Spotlight Stock Market.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Immunovia in any jurisdiction, neither from Immunovia nor from someone else.

This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish an Information Document in the form provided for in Annex IX of the Prospectus Regulation before the subscription period in the Rights Issue begins. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness. Vator Securities are acting for Immunovia in connection with the Rights Issue and no one else and will not be responsible to anyone other than Immunovia for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. Vator Securities are not liable to anyone else for providing the protection provided to their customers or for providing advice in connection with the Rights Issue or anything else mentioned herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Spotlight Stock Market's rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment").

Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channel.